Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Controlled Trial to Explore Interaction Between Aspirin and Clopidogrel in Stable Patients With Previous Myocardial Infarction or Coronary Artery Stent.

Next Previous
Trial Profile

Randomized Controlled Trial to Explore Interaction Between Aspirin and Clopidogrel in Stable Patients With Previous Myocardial Infarction or Coronary Artery Stent.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin (Primary) ; Clopidogrel (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Embolism and thrombosis; Postmyocardial infarction
  • Focus Pharmacokinetics
  • Acronyms Interaction-2

Most Recent Events

  • 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 29 Nov 2012 Planned End Date changed from 1 Apr 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
  • 01 Aug 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top